Recurrent ovarian carcinoma: diagnosis and second-line therapy
Geary, M.; Foley, M.; Lenehan, P.; Murphy, J.; Fennelly, J.
Irish Medical Journal 88(2): 68-70
1995
ISSN/ISBN: 0332-3102 PMID: 7775151 Document Number: 445783
Approximately 10% of patients with ovarian cancer will develop a recurrence. Successful treatment of recurring disease has been documented, and recent developments in chemotherapy are encouraging. In our study, CA125 Tumour Marker was a useful marker to monitor the course of such disease, and detected recurring ovarian cancer at a sub-clinical level, leading to earlier diagnosis. This may have implications for outcome.
Document emailed within 1 workday
Related Documents
Lotze, W. 1991: Current aspects of diagnosis, therapy and follow-up care of ovarian carcinoma Zeitschrift für Arztliche Fortbildung 85(6): 242-245Priolo, D.; Antonelli, G.; Calì, S.; Colina, P.; Giuffrida, D.; Malaponte, E.; Mattina, M.; Parisi, A.; Sambataro, D.; Vitale, F.; Ferraù, F. 2001: Second-line chemotherapy and new drugs for ovarian carcinoma La Clinica Terapeutica 152(1): 39-50
Uehara, S.; Soh, K.; Hoshiai, H.; Yajima, A.; Suzuki, M.; Abe, H. 1983: Establishment and characterization of human ovarian endometrioid carcinoma cell line Nihon Sanka Fujinka Gakkai Zasshi 35(1): 19-26
Mou, H.Z.; Xu, S.H.; Zhang, Y.Y. 1994: The establishment of human ovarian carcinoma cell line HO-8910 and its characteristics Zhonghua Fu Chan Ke Za Zhi 29(3): 162-164; 191
Markman, M. 2008: Second-line therapy for ovarian cancer Clinical Advances in Hematology and Oncology: H&o 6(6): 421-422
Scotto, V.; Sbiroli, C. 1991: Weekly cis-platinum as third line chemotherapy in advanced ovarian carcinoma. Phase Ii study European Journal of Gynaecological Oncology 12(1): 51-53
Piver, M.S.; Lele, S.; Barlow, J. 1980: Weekly cis-diamminedichloroplatinum(II): active third-line chemotherapy in ovarian carcinoma--a preliminary report Cancer Treatment Reports 64(12): 1379-1382
Chan, T.C.; Howell, S.B. 1985: Mechanism of synergy between N-phosphonacetyl-L-aspartate and dipyridamole in a human ovarian carcinoma cell line Cancer Research 45(8): 3598-3604
Lehoczky, O.ó; Pulay, T.ás. 2003: Early results of first-line chemotherapy with paclitaxel and carboplatin in patients with epithelial ovarian carcinoma Orvosi Hetilap 144(28): 1381-1384
Li, Z.-t.; Wu, X.-h.; Fu, S.-l. 2004: Benefit of palliative surgery for bowel obstruction in recurrent ovarian carcinoma Zhonghua Fu Chan Ke Za Zhi 39(4): 260-263
Sham, J.S.T.; Tang, T.C-M.; Fang, Y.; Sun, L.; Qin, L-Xiu.; Wu, Q-Liang.; Xie, D.; Guan, X-Yuan. 2002: Recurrent chromosome alterations in primary ovarian carcinoma in Chinese women Cancer Genetics and Cytogenetics 133(1): 39-44
Menczer, J.; Ben-Baruch, G.; Rizel, S.; Brenner, H. 1992: Cisplatin in combination with continuous VP16 infusion as second line chemotherapy in ovarian carcinoma. A pilot study European Journal of Gynaecological Oncology 13(4): 316-318
Ruiz van Haperen, V.W.; Veerman, G.; Eriksson, S.; Boven, E.; Stegmann, A.P.; Hermsen, M.; Vermorken, J.B.; Pinedo, H.M.; Peters, G.J. 1994: Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780 Cancer Research 54(15): 4138-4143
Smellie, S.; Lambert, M. 1987: Cross-specificity of the tumour marker CA 19-9: a case of ovarian carcinoma with recurrent venous thrombosis Acta Gastro-Enterologica Belgica 50(2): 241-242
Hosaka, M.; Ebina, Y.; Moriwaki, M.; Hara, Y.; Araki, N.; Todo, Y.; Takeda, M.; Watari, H.; Sakuragi, N. 2007: Successful desensitization using cisplatin after carboplatin-associated hypersensitivity reactions in 3 cases with recurrent ovarian carcinoma Gan to Kagaku Ryoho. Cancer and ChemoTherapy 34(9): 1505-1508
Huang, S.; Kong, B.; Ma, Y.; Jiang, S. 2002: Apoptosis of drug-resistant human ovarian carcinoma cell line 3AO/cDDP induced by arsenic trioxide and its mechanism Zhonghua Yi Xue Za Zhi 82(13): 911-914
Ding, X.-l.; Shen, K.; Lang, J.-h.; Wu, M.; Huang, H.-f.; Pan, L.-y.; Yang, J.-x. 2003: Role of positron emission tomography in diagnosis of recurrent ovarian cancer Zhonghua Fu Chan Ke Za Zhi 38(11): 667-669
Wang, F.-f.; Chen, H.-z.; Xie, X.; Ye, F.; Ye, D.-f.; Lü, W.-g.; Ding, Z.-m. 2004: Phosphorylation of signal transducer and activators of transcription 3 induced by vascular endothelial growth factor in ovarian carcinoma cell line in vitro Zhonghua Fu Chan Ke Za Zhi 39(6): 385-389
Gadducci, A.; Cosio, S.; Fanucchi, A.; Tanganelli, L.; Conte, P.F.; Cristofani, R.; Genazzani, A.R. 2003: Is pretreatment hemoglobin level a predictor of complete response to salvage chemotherapy for recurrent platinum-pretreated ovarian carcinoma? European Journal of Gynaecological Oncology 24(5): 405-410
Shimizu, M.; Miya, T.; Takahashi, A.; Kobayashi, Y.; Kubota, K.; Gemma, A.; Hirose, T. 2017: Nearly Complete Response after Second-Line Therapy with Nab-Paclitaxel Monotherapy in a Patient with Recurrent Advanced Non-Small Cell Lung Cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 44(8): 699-702